Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metreleptin in NASH/NAFLD Associated With Lipodystrophy
NCT01679197Phase 2Completed
- Sponsor
- University of Michigan
- Start
- Oct 2012
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of metreleptin in Nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), sponsored by University of Michigan. Started Oct 2012; status: completed.
02
Drugs
metreleptin
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01679197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01679197.